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Abstract 
In the phase 3 trial of eliglustat in patients with Gaucher disease type 1 already stabilized with 
enzyme therapy (ENCORE), at one year, eliglustat was non-inferior to imiglucerase enzyme 
therapy in maintaining stable platelet counts, hemoglobin concentrations, spleen and liver 
volumes. After this primary analysis period, patients entered a long-term extension phase in 
which all received eliglustat. Duration on eliglustat ranged from 2 to 5 years, depending on 
timing of enrollment (which spanned 2 years), treatment group to which patients were 
randomized, and whether they lived in the United States when commercial eliglustat became 
available. Here we report long-term safety and efficacy of eliglustat for 157 patients who 
received eliglustat in the ENCORE trial; data are available for 46 patients who received eliglustat 
for 4 years. Mean hemoglobin concentration, platelet count, and spleen and liver volumes 
remained stable for up to 4 years. Year to year, all four measures remained collectively stable 
(composite endpoint relative to baseline values) in ≥85% of patients, as well as individually in 
≥92%. Mean bone mineral density Z-scores (lumbar spine and femur) remained stable and were 
maintained in the healthy reference range throughout. Eliglustat was well-tolerated over 4 years; 
4 (2.5%) patients withdrew due to adverse events that were considered related to the study drug. 
No new or long-term safety concerns were identified. Clinical stability assessed by composite 
and individual measures was maintained in adults with Gaucher disease type 1 treated with 
eliglustat who remained in the ENCORE trial for up to 4 years. 
 
Key Words: Gaucher disease type 1, eliglustat, substrate reduction therapy, acid β-glucosidase 
deficiency, imiglucerase, enzyme replacement therapy 
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Introduction 
Gaucher disease type 1 is an inherited lysosomal disorder characterized by deficient activity of 
the enzyme acid β-glucosidase with consequential  accumulation of the substrate, 
glucosylceramide, and its unacylated derivative, glucosylsphingosine, primarily in lysosomes of 
tissue macrophages.1  Pathological accumulation of these glycosphingolipids is associated with  
multisystemic disease manifestations, most notably hepatosplenomegaly, accompanied by 
anemia, thrombocytopenia, and bone disease.1 
For 25 years, enzyme replacement therapy for Gaucher disease type 1 has been the mainstay of 
treatment. This usually involves alternate-week infusions of recombinant mannose-terminated 
human acid β-glucosidase, which is targeted to the pathological macrophages; here it augments 
the residual enzyme activity to enhance recycling of β-glucosylceramide. Enzyme therapy can 
reverse the hematological and visceral complications of the disease and can prevent bone 
damage; it improves the quality-of-life for people with Gaucher disease.2-5 Eliglustat is an oral 
substrate reduction therapy approved in the United States in 2014 and European Union in 2015 
for adults with Gaucher disease type 1 who are extensive, intermediate, or poor CYP2D6 
metabolizers  (>90% of patients). Eliglustat acts by partially inhibiting the de novo biosynthesis 
of β-glucosylceramide, thereby rebalancing the rate of formation of the primary substrate of the 
deficient enzyme with its impaired degradation. In clinical Phase 2 and 3 studies of previously 
untreated patients with Gaucher disease type 1, eliglustat induced clinically meaningful 
improvements in hematological parameters as well as spleen and liver volumes at 9–12 
months,6,7 which were maintained at 18 months8 and after 4 years.9 Bone mineralization density 
also improved after 1 year of eliglustat therapy.8,10,11  
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In the Phase 3 ENCORE trial (NCT00943111) of eliglustat treatment for patients with Gaucher 
disease type 1 already stabilized with enzyme therapy, after one year of treatment, eliglustat was 
found to be non-inferior to imiglucerase in maintaining stable platelet and hemoglobin 
parameters, as well as spleen and liver volumes.12 Bone parameters and quality-of-life measures 
also remained stable.12 After the 12-month primary analysis period, patients were offered 
enrollment in a long-term extension phase during which all received eliglustat. Here we report 
the safety and efficacy outcomes from the ENCORE trial over this period. 
Methods  
Study Design  
The ENCORE clinical trial was a randomized, multinational, open-label, non-inferiority study 
comparing eliglustat (Cerdelga®, Sanofi Genzyme, Cambridge, MA, USA) with imiglucerase 
(Cerezyme®, Sanofi Genzyme, Cambridge, MA, USA) as a maintenance therapy in patients with 
Gaucher disease type 1 who had already achieved therapeutic goals while receiving enzyme 
therapy. Detailed methods and the primary outcomes from ENCORE were published 
previously.12  All long-term efficacy and safety analyses were done on the intent-to-treat 
population.  As in the primary analysis, dosing was individualized and based on achieving 
plasma trough levels of at least 5 ng/mL (with doses of 50, 100, or 150 mg eliglustat tartrate 
twice daily); since the Cerdelga product label refers to active base, this corresponds to doses of 
42, 84, and 127 mg, respectively. After the 12-month primary analysis period, all patients had the 
option of continuing in the open-label extension phase of the trial, in which they were treated 
with eliglustat (i.e., patients initially randomized to imiglucerase were switched to eliglustat) and 
followed until the pre-determined end of the study in May, 2015. Thus, patients had the 
opportunity to be treated with eliglustat for 2 to 4.5 years. This was determined by when they 
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enrolled (enrollment spanned 2 years, from September 2009 until November 2011), the initial 
treatment group to which they were randomly assigned, and their country of residence. After 
approval of the drug by the United States Food and Drug Administration in the fall of 2014, trial 
participants living in the United States were discontinued from the study and transitioned to 
commercial eliglustat. 
In the analysis of long-term treatment with eliglustat, baseline was defined as the last available 
assessment prior to eliglustat treatment initiation (Day 1 for patients originally randomized to 
eliglustat and Week 52 + 1 Day for patients originally randomized to imiglucerase). All data 
were analyzed with respect to time on eliglustat treatment rather than time in the trial.  Patients 
were not distinguished on the basis of their original treatment allocation since all patients, 
including those randomized to receive imiglucerase, were receiving enzyme therapy before 
switching to eliglustat.   
Here we report long-term safety and efficacy with respect to years of exposure for all 157 
eliglustat-treated patients in ENCORE; in 46 of these, trial data are available for a period of 4 
years. 
Assessments  
The following parameters were evaluated as described previously: hemoglobin concentration, 
platelet count, spleen volume, liver volume, bone mineral density, biomarkers reflecting the 
activity of Gaucher disease (plasma chitotriosidase activity  [normalized, nmol/hr/mL], plasma 
glucosylceramide [GL-1 in μg/mL], ganglioside GM3 [μg/mL], macrophage inflammatory 
protein 1β [pg/mL], ceramide [mg/L], and sphingomyelin [μg/mL]), and quality-of-life measures 
(mobility, bone pain, Fatigue Severity Score, SF-36, Brief Pain Inventory, and Gaucher Disease 
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Severity Score [DS3]).12  For these analyses, values were examined at the baseline before 
eliglustat was given, and after 1, 2, 3, and 4 years of treatment with the agent. Adverse events are 
summarized by their incidence, seriousness, severity, and relationship to eliglustat and to 
underlying disease. 
Analysis of Disease Stability 
As described previously,12 the composite primary efficacy endpoint of the ENCORE trial was the 
percentage of patients whose hematological parameters and organ volumes remained stable after 
12 months. The stability criteria were defined as those established for these measures in patients 
with Gaucher disease type 1 receiving maintenance treatment with imiglucerase:13 hemoglobin 
concentration that did not decrease by more than 1.5 g/dL; platelet count that did not decrease by 
more than 25%; spleen volume (in non-splenectomized subjects expressed as multiples of 
normal, MN) that did not increase by more than 25%; and liver volume (MN) that did not 
increase by more than 20% from baseline. 
We also determined whether patients met the following pre-specified therapeutic goals for 
hemoglobin, platelet, spleen, and liver parameters based on trial entry criteria and established 
therapeutic goals for patients receiving enzyme therapy13-15: hemoglobin ≥11.0 g/dL for women 
and ≥ 12.0 g/dL for men; platelet count ≥109/L; spleen volume ≤ 8 MN; and liver volume ≤ 1.5 
MN. 
Statistical Analysis 
The analyses include all patients who were treated with eliglustat and were carried out with 
respect to the time (in years) of exposure to eliglustat and not time of engagement in the trial. For 
hemoglobin, platelets, spleen volume, liver volume, lumbar spine Z-score, and femur Z-score, 
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means and 95% confidence intervals over time were determined for the full trial population and 
for the subset of patients who had 4-year data; these are presented graphically for the baseline, 
Year 1, Year 2, Year 3 and Year 4 trial visits. A repeated measures mixed model was undertaken 
for hemoglobin concentration, platelet count, spleen volume, liver volume, and lumbar spine and 
femur Z-scores to assess linear trends during the prolonged course of this trial. Predictor 
variables included the corresponding baseline assessment and time on eliglustat. A logistic 
regression analysis was performed to ascertain if not achieving the trial composite endpoint at 
any point during the trial correlated with age (as a continuous variable), splenectomy status 
(spleen/no spleen), or obesity status (obese/non-obese). 
Achievement of stability with respect to the trial endpoints (individually for hemoglobin, 
platelets, spleen volume, and liver volume, as well as the composite primary endpoint of all four 
stability parameters) is summarized by parameter and by year of visit. Stability with respect to 
the predefined absolute therapeutic goal thresholds for hemoglobin, platelets, spleen volume, and 
liver volume is also summarized by parameter and year, individually and collectively. For both 
measures of stability, the percentages of patients reaching the goals and binomial exact 95% 
confidence intervals were calculated based on the number of patients at risk (i.e., patients with a 
measurement for the parameter of interest) at each visit for each goal individually and for all four 
goals collectively. 
Adverse events are set out in terms of relatedness to eliglustat treatment. In particular, events 
deemed related by investigators that occurred in more than 5% of patients are presented by 
number of patients as well as the number of events. Percentages of patients in each category 
were calculated from the total number treated with eliglustat in the one-year primary analysis 
 8 
 
study or during the extension period. Compliance was determined by the number of pills that 
were returned at each study visit. 
Results 
Patient Disposition and Characteristics 
Of 157 patients who entered the trial and were treated with eliglustat, 148 completed 1 year of 
treatment with eliglustat, 139 completed 2 years, 115 completed 3 years, and 46 completed 4 
years of treatment (Figure 1). Of the 111 patients who did not complete 4 years of treatment with 
eliglustat, 36 switched to commercial eliglustat when it became available in the fall of 2014; 48 
patients timed out of the trial for logistical reasons when it ended before they had accrued 4 years 
of follow-up. Overall, 12 patients withdrew from the trial as a result of an adverse event, 10 
decided to withdraw for reasons unrelated to adverse events (including one withdrawal after 4 
years of treatment), four because of pregnancy (one pregnancy occurred after 4 years of 
treatment), two on account of noncompliance, and one subject was lost to follow-up as a result of 
international travel. A further 15 patients moved to commercial eliglustat after receiving 
eliglustat for 4 years but before the trial had ended. Demographic and baseline disease 
characteristics for the eliglustat-treated patients who completed 4 years of treatment were similar 
to those for all eliglustat-treated patients who entered the trial (Table 1). 
Maintenance of Stable Gaucher Disease Hematological and Visceral Parameters 
Throughout the trial, mean values for hemoglobin concentration, platelet count, spleen volume, 
and liver volume remained stable among all eliglustat-treated patients and in the subset of 
patients who had 4-year data (Figure 2, A-D), with no clinically significant changes from the 
baseline values attained after a mean of 10 years of enzyme therapy.  There were small but 
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statistically significant reductions in least-square mean liver (3%, P=0.02) and spleen volumes 
(13%, P<0.001) after 4 years of eliglustat treatment (Table 2). With respect to the primary and 
secondary clinical endpoints, year to year, all four measures remained collectively stable 
(composite primary endpoint relative to baseline values) in ≥85% of patients and individually in 
≥92% of patients (secondary endpoints) (Figure 3A). With respect to pre-specified therapeutic 
goals established for patients on enzyme therapy,14,15 thresholds for hemoglobin, platelets, 
spleen, and liver were maintained collectively in ≥92% of patients and each individual goal was 
maintained in ≥94% of patients (Figure 3B).  
Most patients who did not achieve the primary composite endpoint missed on a single criterion, 
and this group varied from year to year.  Only one patient missed more than two criteria at once; 
this patient missed spleen, platelets, and liver at one time point.  Among patients with at least 2 
years on eliglustat, six patients missed the composite endpoint at all time points (five 
consistently missed the platelet endpoint, three patients missed the spleen endpoint one or more 
times, and one patient missed the liver endpoint one time). No common clinical characteristics in 
this group were identified.  The logistic regression analysis found no correlation between age, 
gender, splenectomy status, or obesity status with inability to meet the composite endpoint.  
Maintenance of Stable Bone Mineral Density 
Active bone disease was an exclusion criterion for this trial; patients could not have experienced 
bone crisis or symptomatic bone disease (bone pain attributable to osteonecrosis or pathological 
fractures within the year before randomization).12  Mean baseline bone mineral density scores for 
the lumbar spine and femur were found to be within the age-matched reference range for healthy 
individuals. These values were maintained throughout the 4 years of eliglustat treatment (Figure 
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2, E and F). Of note, after 4 years of treatment with eliglustat, lumbar spine least-square mean Z-
scores increased by 0.29 (P<0.0001) (Table 2). 
 
Biomarkers, Gaucher Disease Severity, and Quality-of-Life 
The respective activity measures and concentrations of disease-related biomarkers are set out in 
Table 3. Median activities of chitotriosidase and concentrations of macrophage inflammatory 
protein 1β were elevated at baseline and decreased modestly over 4 years. Plasma concentrations 
of GL-1 and GM3 ganglioside were in the healthy reference range at baseline but decreased by 
>50% during the first 3 months of exposure to eliglustat, consistent with the systemic action and 
diffusible nature of this agent; thereafter these biomarkers remained stable and within the healthy 
normal range over the period of investigation up to 4 years. Median concentrations of the 
bioactive sphingolipids, ceramide and sphingomyelin, were in the normal reference range at 
baseline; over 4 years, ceramide was unchanged and sphingomyelin increased slightly but 
remained well within the normal reference range for healthy subjects.  
No clinically significant changes in any Gaucher disease or quality-of-life measures were 
observed over 4 years. The mean baseline Fatigue Severity Scale score was 3.0 (1=least severe, 
7=most severe) and remained between 3.0 and 3.2 (median scores ranged from 2.7 to 2.9).  The 
mean baselines for the SF-36 mental and physical component scores were 52 and 51, 
respectively (mean score for a normal comparator population=50); both remained between 50 
and 51 (median scores ranged from 52 to 56).  For the Brief Pain Inventory, mean average pain 
score at baseline was 1.4 (0=non-interference, 10=maximal interference) and remained between 
1.4 and 1.6 (median score remained between 0 and 1). For the Gaucher Disease Severity Scoring 
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System (DS3), the mean total baseline score was 2.2 (0=best, 19=worst score) and remained 
between 2.0 to 2.3 (median was 2.0 at all time points).  At baseline, 95% of patients reported 
unrestricted mobility, and this percentage remained between 95% and 97% year to year. Three 
(2%) patients reported a bone crisis while being treated with eliglustat, including one patient who 
also had a bone crisis at baseline. Of the 141 patients who responded to a treatment preference 
survey (oral versus intravenous enzyme treatment) after 1 year of eliglustat, 98% expressed a 
preference for oral therapy; the main reason cited was “convenience.” Of the three patients who 
did not prefer oral treatment, two were undecided and one preferred intravenous treatment 
because it is given in hospital. 
Compliance 
Overall, 90% of patients took ≥90% of their pills, 6% took ≥80 to <90% of their pills, 3% took 
≥70 to <80%, and 2% took ≥40 to <60% of their pills.   
Adverse Events 
The adverse event data set out in Table 4 reflect 511 patient-years of exposure to eliglustat. 
Seventy-four percent of adverse events were mild, 23% were moderate, and 3% were considered 
severe. Four (2.5%) patients withdrew for adverse events considered related to eliglustat, all of 
which occurred during the patients’ first 9 months of eliglustat treatment and all resolved: mild 
lethargy and exfoliative rash (0.1 years), severe upper abdominal pain (0.3 years), moderate 
palpitations (0.54 years) with no clinically relevant ECG findings, and mild vertigo (0.83 years). 
Two serious adverse events considered possibly related to eliglustat by the investigator occurred 
in two patients; neither led to withdrawal from the study: one moderate event of peripheral 
neuropathy and one severe event of bowel obstruction due to Meckel’s diverticulum.  
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Discussion 
The primary analysis from the ENCORE trial clearly showed that eliglustat was non-inferior to 
imiglucerase in its capacity to maintain parameters indicating disease that was stable for 1 year.12 
The analysis reported here, representing 511 patient-years of eliglustat exposure, shows long 
term safety and tolerability along with stable disease parameters and maintenance of therapeutic 
goals for up to 4 years in the cohort of patients assigned to receive eliglustat and the original 
imiglucerase cohort who later moved to eliglustat treatment after participation in the first year of 
the trial. Mean absolute values for hemoglobin concentration, platelet count, spleen volume, liver 
volume, and lumbar spine and femur Z-scores remained stable over 4 years. While, for the 
reasons set out, the number of patients available for analysis after 4 years of treatment under the 
constraints of a clinical trial was considerably reduced, the statistical analysis using a repeated 
measures mixed model to detect linear trends identified modest but statistically significant 
improvements in spleen volume, liver volume, and lumbar spine Z-scores. While these results 
should be interpreted cautiously because of the fewer patients from whom 4-year data are 
available, analysis of the response parameters in this subset reveals the same long-term trends as 
in the trial cohort.  
Biomarkers reflecting Gaucher disease activity were also found to be stable or showed modest 
improvement over time. Quality-of-life measures, which indicated a relatively mild burden of 
disease at baseline, also remained stable for up to 4 years in patients receiving eliglustat, 
indicating that the quality-of-life that they had achieved after a mean of 10 years on enzyme 
therapy was maintained while they were taking eliglustat therapy in the long term. 
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Only 4 patients (2.5%) withdrew from this long-term trial due to adverse events considered to be 
treatment related; no patient withdrew from the study because of  any significant clinical 
deterioration. Most patients who did not meet the primary composite trial endpoint of stability 
relative to their baseline values remained clinically stable, as evidenced by the higher proportion 
of patients year to year who maintained absolute values within the pre-specified thresholds for 
therapeutic goals (Figure 3). Because trial stability goals were defined relative to each patient’s 
individual baseline, patients could (and often did) fail to meet the composite endpoint due to a 
clinical value that did not signify deterioration. For example, a patient whose baseline liver 
volume increased from 0.9 multiples of normal (MN) at baseline to 1.1 MN would fail to meet 
the composite endpoint, as this represents a >20% increase in liver volume, despite the fact that 
the actual value of 1.1 is well within established therapeutic goals for Gaucher patients. There 
were no apparent predictors of inability to meet the composite trial endpoint, including age, sex, 
and splenectomy status. Obesity was also evaluated, due to the possibility that drug distribution 
could be lower in obese individuals.  
No new safety concerns were identified in this long-term trial; this is consistent with a combined 
analysis of adverse event data from all four phase 2 and 3 eliglustat clinical trials.16 Only seven 
types of adverse events considered related to treatment by the investigator were reported in 5% 
or more of patients, with the most common being upper abdominal pain, reported in 7% of 
patients. Three of the seven most common related adverse events in the trial are also known to be 
common in Gaucher disease: fatigue, arthralgia, and abnormal nerve conduction studies.  Of 
note, as in all clinical trials of eliglustat hitherto, we did not see the pattern of chronic diarrhea, 
weight loss, or new tremor, which led to high rates of drug discontinuation in clinical trials of 
miglustat (Zavesca, Actelion, Allschwil, Switzerland), the first commercially available substrate 
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reduction therapy, approved as a second-line treatment for adults with Gaucher disease who are 
not candidates for enzyme therapy.17,18 
Despite the salutary findings of this study, we recognize that there are a few inherent limitations. 
During the long-term extension phase of ENCORE, there was no comparator group because all 
patients were taking eliglustat, thus no direct comparison can be made over this period with 
patients who continue to receive long-term enzyme therapy. Although  it has been suggested that 
relapse is uncommon once patients with Gaucher disease type 1 have had their bulk disease 
controlled with enzyme therapy,19 the effects of the constrained supply of imiglucerase in 2009-
2012 show that clinical deterioration does occur in as little as 3 months with treatment 
interruption.20,21 In our study, clinical stability was maintained with respect to hemoglobin 
concentration, platelet count, liver and spleen volume, bone mineral density and Gaucher 
biomarkers for up to 4 years, well beyond the interval that might be attributed to residual effects 
of prior long-term enzyme replacement therapy.  Although we are encouraged by the long-term 
maintenance of bone health, because the population had no active bone disease at baseline, data 
from this trial do not address the question of whether eliglustat can reverse pre-existing bone 
disease.     
Patients with Gaucher disease are known to be at increased risk of both Parkinson disease and 
hematologic malignancies.22,23 It will be important to evaluate the impact (if any) of eliglustat on 
incidence of these concomitant diseases in long-term observational studies; however, since the 
drug does not cross the blood-brain  barrier, we would not expect a salutary effect of eliglustat on 
Parkinson disease. 
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Long-term eliglustat compliance was good, with 96% of patients taking at least 80% of their 
pills. Notably, this long-term analysis included all eliglustat-treated patients, unlike in the 
primary efficacy analysis, which, as a non-inferiority trial, had excluded two patients whose 
study drug compliance was less than 80%. It will be important to monitor “real world” 
compliance and its impact on drug efficacy, as compliance rates are likely to decrease outside of 
a clinical trial setting.  
Like many other oral drugs, eliglustat is metabolized primarily through the cytochrome P450 
2D6 (CYP2D6) pathway.  Dosing in the eliglustat trials was titrated with the aim of maintaining 
a plasma trough level ≥5 ng/ml, at which half-maximal inhibition of glucosylceramide synthase 
is predicted to occur. However, subsequent pharmacokinetic analyses of clinical trial data 
established that the major determinant of plasma trough level of eliglustat was the patient’s 
CYP2D6-metabolizer status, and that achievement of the target 5 ng/ml level was not necessary 
for drug efficacy.24  Therefore, dosing in the drug label is based on the predicted CYP2D6 
phenotype, as determined by genetic testing. The label also makes recommendations with regard 
to concomitant medications that might either inhibit efficacy of eliglustat or increase plasma 
drug levels.25,26 As in the general population,27 approximately 90% of patients with Gaucher 
disease are intermediate or extensive CYP2D6 metabolizers, with the remainder being poor 
metabolizers, ultra-rapid metabolizers, or unknown. Of note, the ENCORE trial included seven 
patients with an ultra-rapid CYP2D6 metabolizer genotype, for whom eliglustat would be 
contraindicated in drug labels due to insufficient information about this small patient subgroup; 
all seven of these patients met the primary composite endpoint throughout the trial.  
We conclude that clinical stability, judged by composite and individual measures, was 
maintained in eliglustat-treated patients with Gaucher disease type 1 who remained in the 
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ENCORE trial for up to 4 years. Eliglustat was generally well-tolerated and no new or long-term 
safety concerns were identified.   
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Table 1. Demographics and baseline patient characteristics 
 Parameter 
All Eliglustat-treated 
Patients 
(N=157) 
Extension Patients 
with 4-Year Data 
(N=46) 
 Sex, n (%)   
  Male 72 (46) 20 (44) 
  Female 85 (54) 26 (57) 
Age at start of eliglustat* (yr) (mean±SD) 38.0±14.0 34.0±14.4 
Age at first symptom (yr) (mean±SD) 13.9±12.8 10.1±8.6 
Age at diagnosis (yr) (mean±SD) 18.8±13.9 14.8±11.9 
Gaucher disease genotype, n (%)   
L444P/Other 2 (1.3) 0 
N370S/L444P 56 (35.7) 21 (45.7) 
N370S/N370S 35 (22.3) 6 (13.0) 
N370S/Other 47 (29.9) 17 (37.0) 
Other/Other 17 (10.8) 2 (4.3) 
Splenectomy performed, n (%)    
   Partial 2 (1) 2 (4) 
   Total 37 (24) 13 (28) 
Years on ERT prior to eliglustat (mean±SD) 10.5±4.1 9.4±4.5 
CYPD2D6 metabolizer status, n (%)   
Poor 6 (3.8) 3 (6.5) 
Intermediate 21 (13.4) 3 (6.5) 
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Extensive 122 (77.7) 37 (80.4) 
Ultrarapid 5 (3.2) 3 (6.5) 
Indeterminate 3 (1.9) 0 
*Age on day 1 of first dose of eliglustat. 
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Table 2. Least-square mean changes from baseline in hematological, visceral, and bone 
parameters from repeated measures mixed model  
Parameter 
LS Mean  
(95% CI) 
LS Mean Change from 
Baseline (95% CI) 
P value 
Hemoglobin (g/dL)    
Baseline (n=157) 13.7 (13.6, 13.8) — — 
Year 1 (n=151) 13.6 (13.4, 13.7) -0.11 (-0.27, 0.06) 0.19 
Year 2 (n=139) 13.6 (13.4, 13.7) -0.09 (-0.27, 0.09) 0.31 
Year 3 (n=110) 13.6 (13.5, 13.8) -0.04 (-0.23, 0.15) 0.67 
Year 4 (n=45) 13.9 (13.7, 14.1) 0.26 (-0.01, 0.50) 0.06 
Test for Linear Trend (B,1,2,3,4) — — 0.05 
Platelet Count (109/L)    
Baseline (n=157) 200.3 (194.4, 206.1) — — 
Year 1 (n=151) 206.7 (200.7, 212.7) 6.42 (-1.43, 14.26) 0.11 
Year 2 (n=139) 202.4 (196.2, 208.6) 2.13 (-6.35, 10.60) 0.62 
Year 3 (n=110) 210.7 (203.8, 217.6) 10.40 (1.35, 19.45) 0.02 
Year 4 (n=45) 209.9 (199.2, 220.7) 9.63 (-2.63, 21.88) 0.12 
Test for Linear Trend (B,1,2,3,4) — — 0.09 
Spleen Volume (MN)    
Baseline (n=120) 3.1 (3.0, 3.2) — — 
Year 1 (n=115) 2.9 (2.9, 3.0) -0.14 (-0.22, -0.05) 0.002 
Year 2 (n=105) 2.9 (2.8, 3.0) -0.20 (-0.31, -0.09) 0.0003 
Year 3 (n=80) 2.9 (2.8, 3.0) -0.21 (-0.35, -0.10) 0.0004 
Year 4 (n=33) 2.7 (2.5, 2.8) -0.39 (-0.55, -0.22) <0.0001 
Test for Linear Trend (B,1,2,3,4) — — <0.0001 
Liver Volume (MN)    
Baseline (n=157) 0.94 (0.929, 0.956) — — 
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Parameter 
LS Mean  
(95% CI) 
LS Mean Change from 
Baseline (95% CI) 
P value 
Year 1 (n=151) 0.95 (0.94, 0.97) 0.01 (-0.01, 0.03) 0.17 
Year 2 (n=136) 0.95 (0.94, 0.97) 0.01 (-0.01, 0.03) 0.29 
Year 3 (n=110) 0.95 (0.94, 0.97) 0.01 (-0.01, 0.03) 0.46 
Year 4 (n=46) 0.91 (0.89, 0.94) -0.03 (-0.06, -0.004) 0.03 
Test for Linear Trend (B,1,2,3,4) — — 0.04 
Total Spine Z-score    
Baseline (n=153) -0.3 (-0.3, -0.2) — — 
Year 1 (n=144) -0.2 (-0.2, -0.1) 0.07 (0.03, 0.11) 0.002 
Year 2 (n=132) -0.1 (-0.2, -0.09) 0.11 (0.06, 0.17) <0.0001 
Year 3 (n=104) -0.09 (-0.1, -0.04) 0.16 (0.10, 0.23) <0.0001 
Year 4 (n=42) 0.04 (-0.04, 0.1) 0.29 (0.20, 0.38) <0.0001 
Test for Linear Trend (B,1,2,3,4) — — <0.0001 
Total Femur Z-Score    
Baseline (n=151) 0.03 (-0.007, 0.060) — — 
Year 1 (n=139) 0.07 (0.034, 0.103) 0.04 (0.013, 0.072) 0.005 
Year 2 (n=129) 0.05 (0.018, 0.088) 0.03 (-0.012, 0.065) 0.17 
Year 3 (n=103) 0.08 (0.044, 0.120) 0.06 (0.011, 0.101) 0.02 
Year 4 (n=39) 0.07 (0.018, 0.131) 0.05 (-0.015, 0.111) 0.13 
Test for Linear Trend (B,1,2,3,4) — — 0.14 
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Table 3. Median changes in plasma biomarkers from baseline to 4 years 
 
Endpoint 
Baseline 
Median (min, max) 
4 Years 
Median (min, max) 
Change from Baseline 
Median (min, max) 
Percent Change  
from Baseline 
Median (min, max) 
Normalized chitotriosidase 
activity (nmol/hr/mL) 
605  
(0, 10761) 
n=99 
363  
(4, 3916) 
n=30 
-310  
(-3397, 859) 
n=26 
-63  
(-98, 81) 
n=26 
Plasma glucosylceramide 
(GL-1) (μg/mL) 
5.10  
(2.2, 16.9) 
n=155 
2.00  
(2.0, 5.3) 
n=42 
-3.35  
(-8.4, 0.4) 
n=42 
-60.36  
(-80.8, 8.2) 
n=42 
Plasma GM3 (μg/mL) 13.0  
(7, 30) 
n=136 
6.0  
(4, 15) 
n=43 
-7.0  
(-23, 0) 
n=29 
-55.6  
(-82, 0) 
n=29 
Plasma ceramide (mg/L) 3.90  
(2.2, 8.3) 
n=154 
3.80  
(2.5, 6.4) 
n=43 
-0.60  
(-2.4, 1.6) 
n=43 
-13.33  
(-40.0, 66.7) 
n=43 
Plasma sphingomyelin 
(μg/mL) 
318.0  
(200, 596) 
n=154 
434.0  
(224, 645) 
n=43 
133.0  
(0, 362) 
n=43 
41.8  
(0, 127) 
n=43 
Plasma macrophage 
inflammatory protein 1β  
(MIP-1β)(pg/mL) 
51.65  
(9.3, 433.8) 
n=152 
55.30  
(15.6, 193.7) 
n=38 
-21.78  
(-279.3, 114.4) 
n=38 
-31.45  
(-83.3, 289.3) 
n=38 
Normalized chitotriosidase: values were doubled for patients who had heterozygous chitotriosidase genotypes for the common null (24 
base-pair duplication) mutation. Patients who have a chitotriosidase genotyping category of “homozygous mutation” have no expected 
chitotriosidase activity and therefore, their values for below the level of quantification were set equal to missing for this analysis. 
Normal ranges:  Chitotriosidase = 4–120 nmol/h/mL; Plasma GL-1 =≤2·0 to 6·6 μg/mL; GM3 = 5 to 21 μg /mL; ceramide = μg/mL; 
1.8-6.5; sphingomyelin = <200-703 μg/mL; MIP-1β = 27·3 to 77·2 pg/mL 
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Table 4. Summary of adverse events 
 
Patients 
(N=157) 
Any patient with adverse event* (n, %) 147 (94) 
Severity by event*  
Mild (number of events, %) 1592 (74) 
Moderate (number of events, %) 502 (23) 
Severe (number of events, %) 62 (3) 
Patients reporting at least 1 related adverse event (n, %) 84 (54) 
Patients reporting at least 1 serious adverse event (n, %) 27 (17) 
Patients with adverse event leading to withdrawal (n, %) 12 (8) 
Deaths 0 
Related adverse events by patient** in ≥ 5% of patients (n, %) 81 (53) 
Abdominal pain upper 11 (7) 
Arthralgia 9 (6) 
Dyspepsia 9 (6) 
Fatigue 8 (5) 
Gastritis 8 (5) 
Diarrhea 8 (5) 
Nerve conduction studies abnormal 8 (5) 
*Regardless of relationship to eliglustat 
**Considered by investigator to be possibly, probably, or definitely related to eliglustat. Two related AEs in two 
patients were considered serious and possibly related to eliglustat (neither lead to trial withdrawal): 1 peripheral 
neuropathy (moderate), 1 bowel obstruction due to Meckel’s diverticulum (severe) 
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Figure 1. Patient disposition 
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Figure 2. Mean for hematologic, visceral, and bone parameters over four years of eliglustat 
treatment. Error bars denote upper and lower 95% confidence intervals.  
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Figure 3. Stability of hematologic and visceral parameters with respect to (A) the composite 
primary endpoint (relative to change from baseline) and (B) prespecified therapeutic goals 
based on entry criteria and goals established for patients on enzyme therapy (absolute 
value). Error bars denote upper and lower 95% confidence intervals. 
 
A. 
 
B. 
 
 
Figure legend:  
The N’s for each year represent the number of overall patients in the trial at that time point.  The number of patients 
represented for each individual assessment varied slightly and were lower for spleen measures as they excluded 
splenectomized patients. 
 
